The latest review of medications approved by the US Food and Drug Administration for the treatment of patients with dementia shows that even though the drugs pass muster statistically on scales that measure patients' cognitive function, they produce little if any clinically meaningful benefit (Raina P et al. Ann Intern Med. 2008;148:379-397). Results of the review, experts say, point to an urgent need for more thorough, independent research on the pharmacologic treatment of dementia.
Voelker R. Guideline: Dementia Drugs’ Benefits Uncertain. JAMA. 2008;299(15):1763. doi:10.1001/jama.299.15.1763
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: